- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06526507
PrEPARE-SCALE: Scaling up Integrated PrEP Delivery in Kenyan Maternal and Child Health Clinics
PrEPARE-SCALE: Scaling up Integrated PrEP Delivery in Kenyan Maternal and Child Health Clinics for Pregnant and Postpartum Women
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Aim 1: To develop and determine the impact of a Community of Practice (CoP) on stakeholder and healthcare worker engagement and knowledge of integrated pre-exposure prophylaxis (PrEP) delivery.
Aim 2: To determine the impact of a 3-component scale-up package on implementation outcomes and PrEP patient outcomes among pregnant and postpartum populations.
Aim 2a: To determine the impact of the scale-up package on PrEP implementation outcomes, including reach, service penetration, adoption (primary outcomes), and PrEP fidelity and maintenance (secondary outcomes).
Aim 2b: To determine the impact of the scale-up package on PrEP patient outcomes, including PrEP initiation and continuation.
Aim 3: To identify difference-making bundles of facility- and regional-level attributes and implementation processes that influence reach, fidelity implementation, and maintenance.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Busia, Kenya
- Busia County Referral Hospital
-
Nairobi, Kenya, MRX5 + 53
- Kenyatta National Hospital
-
-
Nandi
-
Kapsabet, Nandi, Kenya
- Kapsabet County Referral Hospital
-
-
Trans Nzoia
-
Kitale, Trans Nzoia, Kenya
- Kitale County Referral Hospital
-
-
Uasin Gishu County
-
Eldoret, Uasin Gishu County, Kenya
- Uasin Gishu District Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Health Care Workers:
- work at a facility involved in study
- involved in PrEP service delivery
- >=18 years
Clients:
- female clients seeking health services at study facilities
- pregnant or postpartum
- >15 years (includes emancipated minors)
Exclusion Criteria:
- N/A
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Comparison
|
|
|
Experimental: Implementation strategy package
Package includes a Community of Practice, a quality improvement (QI) practice, and a training & delivery toolkit.
|
Package includes a Community of Practice, a quality improvement (QI) practice, and a training & delivery toolkit.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reach
Time Frame: 1 year
|
Number of pregnant and postpartum MCH clients initiated on PrEP each month
|
1 year
|
|
Adoption (facility)
Time Frame: 1 year
|
Proportion of facilities per county that have begun offering PrEP in MCH
|
1 year
|
|
Service penetration
Time Frame: 1 year
|
Number and proportion of pregnant and postpartum maternal child health clinic (MCH) clients who are screened for PrEP
|
1 year
|
|
Adoption (provider)
Time Frame: 1 year
|
Number, proportion, and representativeness of nurses and HIV testing services (HTS) providers who have begun offering or counseling on PrEP in MCH
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anjuli Wagner, PhD, University of Washington
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Blood-Borne Infections
- Urogenital Diseases
- Genital Diseases
- Immune System Diseases
- Infections
- RNA Virus Infections
- Virus Diseases
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Slow Virus Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
- STUDY00019007
- R01MH135730 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.